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Association of 1gM with IgG ANCA in patients presenting with
pulmonary hemorrhage. ANCA are markers for systemic vasculitis
such as Wegener's granulomatosis (WG) and microscopic polyarteritis
(MPA) and are usually of the IgG isotype. However, 1gM ANCA may
rarely occur in isolation, and in these circumstances, we have found
that they are associated clinically with a syndrome of pulmonary
hemorrhage and systemic vasculitis. How frequently 1gM ANCA may
occur in conjunction with IgG has not previously been investigated. We
report here a study of 24 consecutive patients with lgG ANCA-positive
systemic vasculitis (14 WG, 10 MPA) in whom we determined whether
1gM ANCA occurred in association with IgG ANCA, and if so, whether
this had clinical importance. Eight patients were found to have 1gM
ANCA as well as lgG ANCA, and of these, seven presented with severe
pulmonary hemorrhage. None of the 1gM ANCA-negative patients
presented with pulmonary hemorrhage. Although the occurrence of
pulmonary hemorrhage in ANCA positive vasculitis was closely corre-
lated with the presence of 1gM ANCA, the antigen specificity of these
1gM autoantibodies was variable, since both myeloperoxidase (4 pa-
tients), PR3 (3 patients), and an unknown ANCA antigen (I patient)
were found to be targets. We conclude that knowledge of ANCA
isotype may have important clinical and therapeutic implications for the
management of patients with systemic vasculitis.
Circulating anti-neutrophil cytoplasm antibodies (ANCA) are
autoantibodies associated with small vessel vasculitis such as
Wegener's granulomatosis (WG) and microscopic polyarteritis
(MPA), and have been reported to be of the IgG isotype [1—3].
Two patterns of antibody binding have been described by
indirect immunofluorescence: a granular cytoplasmic appear-
ance (C-ANCA) and a predominantly pen-nuclear pattern (P-
ANCA). C-ANCA recognize mainly a 29 kD proteinase termed
PR3 [4—6], and most P-ANCA sera bind to myeloperoxidase
(MPO) [71.
We recently described a subgroup of patients characterized
immunopathologically by the presence of 1gM ANCA alone
(without IgG ANCA), and clinically by pulmonary hemorrhage
[81. However the incidence of pulmonary hemorrhage of 42% in
Wegener's syndrome [9] and 29% in MPA [10] is higher than
can be accounted for by patients with 1gM ANCA alone. The
aim of this study was to analyze the prevalence of 1gM ANCA
at disease onset in patients with IgG ANCA positive vasculitis,
to determine their clinical correlation, and to examine their fine
specificity.
We found that eight of 24 consecutive patients with systemic
vasculitis had 1gM as well as lgG ANCA at their time of
referral, Seven of these had severe pulmonary hemorrhage (4 of
7 requiring assisted ventilation); none of the 1gM negative
patients had clinical evidence of pulmonary hemorrhage. Eight
of eight 1gM positive patients were plasma exchanged, three of
eight on a plasma filter device, which removes 1gM less
efficiently. These three patients seemed to have had a less
satisfactory outcome.
Using purified substrates to determine antigenic specificities,
we found that four patients had 1gM and IgG anti-MPO anti-
bodies. Two patients had 1gM and IgG anti-PR3 antibodies. One
had 1gM anti-PR3 and IgG anti-MPO without 1gM anti-MPO or
IgG anti-PR3, and one had IgG anti-PR3 and 1gM ANCA of
unknown specificity. Competitive binding assays suggested that
the 1gM anti-MPO recognize the same epitope as the IgG
anti-MPO antibodies.
Our findings point to the importance of autoantibody isotype
in determining disease expression in ANCA-positive systemic
vasculitis, and to the value this may have in management.
Methods
Patients
Serum samples were obtained from 24 patients presenting
sequentially to this department with ANCA-positive systemic
vasculitis with a follow-up period which lasted a mean of 9.9
months. Sera were stored in aliquots at —20°C until assayed.
Seven patients had biopsy proven WG, seven had suspected
WG with upper respiratory tract involvement, and 10 had MPA
[10]. There were 15 males and 9 females with mean age being
58.6 (17 to 74 years). The main clinical features at the onset of
the disease are summarized in Table 1.
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ANCA assays
Initial sera were assayed for ANCA activity by solid phase
immunoassay (SPIA) with a neutrophil extract preparation
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1 M MPA KL HD Hemop diffuse
2 F MPA KL HD Hemop + AV diffuse
3 M MPA KLE HD Hemop + AV diffuse
4 M MPA KL HD Hemop diffuse
5 M WG KU >200 Hemop + AV diffuse
6 M WG KLEEySJ >200 Hemop + AV diffuse
7 M W KL >200 Hemop + AV diffuse
8 M MPA KL HD — nodular
9 M WG KEEyJ <200 —
10 F WG EEyJ — —
11 F WG KLEEy HD nodular
12 M WG KEEy >200 —
13 M WG KL >200 nodular
14 F W KES <200 —
15 M W KEyM HD —
16 M W KLEEy <200 nodular
17 F W KLEJN HD nodular
18 M W KLESJ <200 nodular
19 F W KEySN >200 —
20 M MPA KL >200 nodular
21 M MPA KLS <200 nodular
22 F MPA KL <200 nodular
23 F MPA KL >200 pleural effusion
24 F MPA K HD —
Abbreviations are: (Diagnosis) WG, biopsy-proven Wegener's granulomatosis; W, clinically suspected WG; MPA, microscopic polyarteritis;
(Organ involvement) K, kidney; L, lung; E, ENT; Ey, eye; S, skin; J, arthritis; M, muscle; N, nervous system; (Level of renal function) HD,
hemodialysis; <200 or >200 for the level of serum creatinine (jmol/liter); (Lung involvement) presence or absence of hemopt, hemoptysis; AV,
assisted ventilation; shadows on chest X-ray, diffuse or nodular. Patients I to 8 had 1gM and IgG ANCA; patients 9 to 24 had IgG ANCA alone.
These patients were initially diagnosed as having Goodpasture's syndrome, ANCA at referral was also positive
known to contain all the ANCA autoantigens (ANCA SPIA) [2].
Specificity was confirmed by indirect immunofluorescence
(hF). Antigenic specificity was sought by binding to purified
myeloperoxidase (anti-MPO) (Calbiochem, USA) and protein-
ase 3 (anti-PR3) (Bio-Carb, Sweden).
ANCA SPIA. The IgG ANCA RIA was performed as previ-
ously described [2].
The 1gM ANCA ELISA used the same neutrophil extract as
the IgG ANCA RIA, at the same dilution in phosphate-buffered
saline (PBS). Non specific binding sites were blocked with PBS
containing 2% bovine serum albumin (PBS-BSA). Sera were
diluted 1:50 in PBS containing 1% BSA and 0.1% Tween 20
(Sigma Chemical Co., St. Louis, Missouri, USA.) (PBS-BSA-
Tw). Binding was detected by alkaline phosphatase conjugated
polyclonal rabbit anti-human 1gM (Dako, D337) diluted 1:1000
in PBS-BSA-Tw. This anti-human 1gM reagent has been shown
not to cross react with human IgG or IgA in ELISA assays [11].
After addition of the substrate (Sigma 104), the plates were read
in a Titertek ELISA plate reader at 405 nm. All incubations
were 100 pd/well at 37°C for one hour, with triple washes of PBS
containing 0.1% Tween 20 (PBS-Tw) between stages. Controls
included blank and antigen free wells.
In this assay, and those described below, results were ex-
pressed as percentage of binding of a standard laboratory
positive, and normal range was established as the mean of a
panel of normal sera plus two standard deviations.
Anti-MPO assays. An RIA specific for IgG anti-MPO anti-
bodies was performed by modifying the ANCA RIA. In brief,
purified MPO (Calbiochem) was diluted (l02 U/mI) in borate
buffered saline (BBS) 0.1 M pH = 8.4 and coated to flexible
microtiter plates (50 pd/well, Dynatech, UK) before incubation
at 4°C for 16 hours. Remaining binding sites were blocked with
100 p1/well of PBS-BSA. After washing with PBS-Tw, 50
/Ll/well of test, positive and negative control sera were added,
diluted 1:50 in PBS-BSA-Tw. Binding was detected by an 1125
polyclonal labeled goat anti-human IgG antibody (Sigma I 3382;
4 Ci/g; 2 x 106 counts/SO pA). Plates were counted in a
Packard Crystal II multichannel gamma counter. All incuba-
tions were for one hour at 37°C with triple washes of PBS-Tw
between stages.
An 1gM anti-MPO ELISA was also developed. Briefly,
purified MPO (Calbiochem) diluted as above was coated on to
96-well ELISA plates (NUNC), 50 pAIwell for three hours at
37°C or overnight at 4°C, followed by a blocking stage with
PBS-BSA 100 p1/well. The dilutions of sera and anti-human 1gM
monoclonals were identical to those used in the 1gM ANCA
assay. This assay allowed us to find a very strong 1gM anti-
MPO serum which was then used as a reference positive
(100%).
Anti-PR3 assays. IgG anti-PR3 antibodies were detected
using a commercially available ELISA kit (Bio-Carb, Sweden)
according to the manufacturer's instructions. This ELISA has
been shown to detect reactivity to the C-ANCA antigen [12],
now known to be PR3 [6]. This was adapted to detect 1gM
anti-PR3, changing the detection system as for the 1gM ANCA
or MPO assays.
Inhibition studies. The specificity of 1gM binding in the
ANCA SPIA was confirmed by inhibition studies in which an
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inhibition of binding following pre-incubation of test sera with
the neutrophil extract or an irrelevant protein (bovine hemoglo-
bin) in the fluid phase was sought [2].
lIP'. This was performed as previously described [13] using a
conjugate that detected IgG, 1gM and IgA, and was assessed
independently by two investigators. Positive sera were classi-
fied as having a cytoplasmic (C-ANCA) or pen-nuclear (P-
ANCA) pattern. Sera with 1gM ANCA detected by the 1gM
ANCA SPIA were tested by hF using FITC rabbit anti-human
1gM (F203, DAKO, Denmark) diluted 1:32 in place of the
conjugate used for the routine assay.
Antigen limiting concentration for 1gM anti-MPO binding
To optimize an IgMJIgG anti-MPO competition assay, a
lower MPO concentration than for the usual assay was used in
order to allow saturation of the antigen determinants by IgG
anti-MPO antibodies before coating with sera containing 1gM
anti-MPO activity. To determine the MPO concentration to be
used for these studies, microtiter plates were coated with a
decreasing concentration of MPO by serial double dilution
starting from the 10—2 U/mI concentration used in the standard
assay. After the blocking stage, Igo and 1gM positive control
sera were coated 1:50 and binding was detected as described
above, Results were expressed as percentage of the maximum
binding subtracted by the background of the assay in antigen
free wells.
IgM/IgG anti-MPO antibody competitive binding assays
To investigate whether 1gM anti-MPO antibodies recognize
the same epitope as IgG anti-MPO antibodies, competitive
inhibition assays were performed. MPO was coated at the
lowest antigen concentration that gave a good cut-off between
positive and negative sera as determined above. This was half
the concentration used in the standard assay. The three sera
with the highest 1gM anti-MPO activity (N = 3) were co-
incubated, diluted 1:50, either with sera containing IgO but not
1gM anti-MPO antibodies (N = 6) or control sera (N = 5)
diluted 1:20, or IgG for intravenous injection (Sandoglobulin)
diluted to the same final IgG concentration. Binding of 1gM
anti-MPO antibodies was detected as described above. Results
were expressed as the percentage of reduction of the 1gM
anti-MPO activity as compared to the sera incubated with
PBS-BSA-Tw. Inhibition was regarded as significant when it
exceeded two standard deviations from the mean inhibition
obtained with the negative sera, for each tested 1gM anti-MPO
serum.
Anti-glomerular basement membrane (GBM) antibodies
In view of the simultaneous presence of ANCA and anti-
GBM antibodies that we observed in certain patients with renal
or pulmonary-renal involvement [14], reactivity of initial sera
with GBM was assessed by an anti-GBM assay as described
[15].
1gM purjfication
Sera were first depleted of IgG by protein 13 (Pharmacia, UK)
chromatography. The unbound fraction was collected and the
1gM fraction was affinity-purified by chromatography against
protamine sulfate, and eluted with 0.08 M PBS containing 1.1 M
NaCI as previously described [16]. These 1gM fractions were
showed to be free of IgO ANCA activity in the IgG ANCA RIA.
Immunoblot for 1gM anti-MPO antibodies
Neutrophils were isolated on a hypaque gradient as previ-
ously described [2], and resuspended in PBS containing 0.5 mrvi
MgC1, 0.9 mivt CaCI and protease inhibitors (PMSF 1 mM,
EDTA 2 mM) and incubated at 37°C for 30 mn with PMA 1
p.g/ml to induce the release of secondary granules [17]. After
centrifugation the supernatant was removed and the pellet
washed three times with PBS. These neutrophils, depleted of
secondary granules, were then resuspended in 1% Triton X 100
in PBS and left on ice for 40 minutes. This Triton extract was
aliquoted and frozen at —80°C until use. The Triton extract, or
purified MPO (Calbiochem), was run in reducing buffer after
boiling for two minutes. Western blot was performed according
to the method described by Laemmli [18]. Positive and negative
sera for 1gM MPO diluted 1:20 in Tris buffer saline Tween pH 8
(TBST) containing 2% dried skimmed milk (TBSTM), as well as
purified 1gM fractions and polyclonal rabbit anti human MPO
(Dako A398) diluted 1:1000 were incubated with the nitrocellu-
lose strips for three hours at room temperature. After washing
with TBSTM, anti-human 1gM (Dako D337) or anti-rabbit IgU
(Serotec 2ABO2A) alkaline phosphatase conjugated diluted
1:1000 in TBSTM was incubated for one hour. Binding was
detected adding alkaline phosphatase substrate.
Autoreactivity associated with 1gM ANCA positive sera
The presence of rheumatoid factor (RF), anti-nuclear factor
(ANF), anti-smooth muscle, anti-mitochondrial, anti-gastric
parietal cells, anti-reticulin and anti-cardiolipin antibodies was
determined as follows. Sera were screened for RF by latex
agglutination (Ortho Diagnostics, sensitivity 30 lU/liter), and
where present, the level of RF was determined by laser nephe-
lometry (Becton Diagnostics), ANF were detected using Hep2
cells as substrate (Ortho). Anti-dsDNA and anti-cardiolipin
antibodies were measured by ELISA. Anti-smooth muscle,
anti-mitochondrial, anti-reticulin and anti-gastric parietal cells
antibodies were detected by hF using a composite block
containing rat liver, kidney and stomach, and sera diluted 1:10.
Results
ANCA assays
ANCA SPIA. All patients were IgG ANCA positive in their
initial sera. Eight were also found to have 1gM ANCA at the
onset of their disease. Although the patients with IgG and 1gM
ANCA had higher binding in the IgG ANCA SPIA as compared
to the patients with IgG ANCA alone (67.5% vs. 43.8%, P c
0.05), there was a large overlap between the range of IgG
ANCA binding in these two populations (35 to 100% vs. 21 to
87%).
Anti-PR3 and anti-MPO specific assays. For IgG assays, the
patients had either IgG anti-PR3 or anti-MPO antibodies. Only
three had neither of these specificities.
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Table 2. Autoreactivities of the sera from patients with I M ANCA
Four patients had 1gM and IgG anti-MPO antibodies in 1gM
assays. Two patients had 1gM and IgG anti-PR3 antibodies. One
had 1gM anti-PR3 and IgG anti-MPO, without 1gM anti-MPO or
IgG anti-PR3. And one had 1gM ANCA of unknown specificity
and IgG anti-PR3 (Table 2). No attempt was made to compare
the amount of IgG and 1gM ANCA in our patients as the assays
have not been standardized in order to give actual quantitative
data.
Inhibition studies. 1gM ANCA activity was inhibited after
pre-incubation with neutrophil extract in the liquid phase in all
sera by a mean of 88.5% (74 to 100%). Hemoglobin at the same
concentration led to an inhibition of 18.6 10.7% (mean
standard deviation) of the 1gM ANCA binding.
hF. In IgG ANCA hF studies, 14 of 24 were found to have a
C-ANCA and 10 a P-ANCA pattern. One of the sera with
anti-MPO activity produced a C-ANCA pattern on hF (Table 2)
as has occasionally been observed previously [19].
1gM ANCA hF was positive for the eight sera positive for
1gM ANCA in the ANCA SPIA. The pattern of intracellular
immunofluorescence was more diffuse than found in the stan-
dard hF assay, and produced some staining of the cell external
membrane.
Antigen limiting concentration for 1gM anti-MPO binding
As IgG anti-MPO binding decreased linearly entirely over the
range of MPO coating concentration, 1gM anti-MPO antibody
binding appeared to be highly dependent on the antigen coating
concentration. The antigen concentration chosen for the com-
petitive inhibition studies was half of that used in the standard
MPO assay.
Competitive inhibition studies
The binding of 1gM anti-MPO antibodies in the three 1gM
anti-MPO positive sera was significantly displaced from MPO
by at least four of the six IgG anti-MPO positive sera, with a
maximum of 78% inhibition. All IgG anti-MPO sera inhibited
the binding of, at least, one of the 1gM anti-MPO positive sera.
The normal sera and commercial IgG for intravenous injection
produced a mean of 5% inhibition (Table 3).
Immunob/ot for 1gM anti-MPO antibodies
A single band with a molecular weight comparable to that of
the MPO heavy chain was seen with both the serum and the
purified 1gM fraction from a patient positive for 1gM MPO (Fig.
Table 3. Inhibition of 1gM anti-MPO binding (patients 1, 2 and 3) by
IgG anti-MPO (sera A to F)
IgG anti-MPO sera control sera
mean+2sDA B C D E F
1 51 33 37 32 (10) 30 3.3 + 15.2
2 27 26 20 12 (0) (0) 0.9 + 5.6
3 78 47 (21) 30 46 (0) 5.0 + 18
Results are expressed as the percentage of inhibition of the binding of
one of the three sera positive for 1gM anti-MPO (from patient No. 1, 2
and 3) by one of the six sera containing IgG anti-MPO antibodies alone
(sera A to F from our ANCA-positive sera bank). The mean inhibition
+ 2 5D obtained with a panel of control sera is shown. Values in
parentheses are not considered to be significant.
1). In separate experiments, immunoblots on purified MPO
(Calbiochem) with sera containing high titer of IgG anti-MPO
antibodies showed binding only to the MPO heavy chain and
not the MPO light chain, in contrast with the rabbit polyclonal
anti-human MPO which blotted both the light and the heavy
chain (data not shown). Sera with lower titers of IgG or 1gM
anti-MPO antibody did not give positive blotting, in accordance
with preliminary data suggesting that denaturation or reduction
of MPO leads to partial loss of autoantibody reactivity (Falk et
al, Esnault et al, personal communications).
Autoantibody screening
Two of the patients with IgG and 1gM anti-MPO antibodies
had IgG anti-GBM antibodies. One patient with 1gM and IgG
anti-PR3 positivity had rheumatoid factor activity. Other au-
toreactivities, which were at low titer, are summarized in Table
2. None of the patients with ANF or dsDNA had clinical
features of systemic lupus erythematosus.
Correlation between ANCA isotype and clinical disease
Seven of eight patients with 1gM ANCA in their presenting
sera had evidence of pulmonary hemorrhage, with hemoptysis
and diffuse pulmonary shadowing on the chest X-ray. The
patient with 1gM ANCA and no pulmonary hemorrhage had
1gM ANCA of unknown specificity. None of the patients
negative for 1gM ANCA had pulmonary hemorrhage.
All the patients with pulmonary hemorrhage were plasma
exchanged. The method for plasma separation was either cyto-
centrifugation or plasma filtration. Because the characteristics
ANCA
Patients Diagnoses hF
IgG ANCA 1gM ANCA OtherAuto
GBM reactivitySpecificity Titer Specificity Titer
1 MPA P MPO 100 MPO 67 — dsDNA
2 MPA C MPO 49 MPO 41 63 Cardiol
3 MPA P MPO 30 MPO 100 — ANF
4 MPA P MPO 64 MPO 20 84 —
5 WG C PR3 78 PR3 27 — —
6 WG C PR3 44 PR3 59 — RF
7 W P MPO 100 PR3 100 — —
8 MPA C PR3 70 — 20 — ANF
Abbreviations are: IIF, indirect immunofluorescence; P, P-ANCA; C, C-ANCA; GBM, antiglomerular basement membrane antibodies; RF,
rheumatoid factor; ANF, anti-nuclear factor; cardiol, anti-cardiolipin antibodies; dsDNA, anti-double stranded DNA.
a See Table I
Fig. 2. Sequential IgG and 1gM anti-MPO activity of patient 1. The
upper and lower dotted line correspond respectively to the upper limit
of the normal range of the IgG assay (15%) and 1gM assay (8% of a
29 — reference positive control).
1 2 3 4
Fig. 1. Western blot for 1gM anti-MPO activity. A single line corre-
sponding to the size of the MPO heavy chain is obtained when a
neutrophil extract is blotted with a serum with 1gM anti-MPO activity
(lane 2), the 1gM purified fraction of this serum (lane 3) or a polyclonal
rabbit anti human MPO (Dako A398) (lane 4), but not with a control
serum (lane 1).
of the plasma filter used predicts that 1gM would be less
effectively removed (sieving coefficient 1 only up to 94 kd), we
examined the clinical and serological evolution of the patients
according to the method used for plasma separation. One 1gM
positive patient (No. 6) was exclusively plasma exchanged
using a plasma filter device. No significant 1gM ANCA activity
could be demonstrated in his plasma exchange fluid. His
respiratory condition deteriorated and he subsequently died.
One other patient (No. 1) had a single plasma exchange using a
cytocentrifuge followed by subsequent treatments with a
plasma filter device. The levels of his 1gM ANCA activity were
characterized by a sharp drop following the initial treatment
with the cytocentrifuge (Fig. 2). Large amounts of 1gM ANCA
activity were recovered from the plasma exchange fluid. During
the subsequent plasmapheresis, using a plasma filtration device,
the slow rate of fall of 1gM ANCA activity was matched by the
patients' slow recovery. One patient (No. 4) had pulmonary
hemorrhage in association with anti-GBM antibodies. After
plasma exchange treatment, the patient recovered. Subse-
quently, he relapsed even though anti-GBM levels had fallen
nearly to background. At this stage there were significant
quantities of 1gM anti-MPO antibodies detected for the first
time.
Discussion
We showed that, at presentation, 8 out of 24 patients with
systemic necrotizing vasculitis had 1gM ANCA in association
with IgG ANCA. The validity of this finding was supported by
indirect immunofluoreseenee, antigen inhibition of the ANCA
binding by preincubation in the liquid phase, antigen-specific
solid phase assays and the absence of rheumatoid factor in all
but one patient. In addition, by Western blot analysis, we were
able to show 1gM anti-MPO activity in one strong positive
serum and its purified 1gM fraction. All 1gM ANCA positive
patients, except one, had severe pulmonary hemorrhage. The
only patient (patient 8) with 1gM ANCA and no evidence of
pulmonary hemorrhage had 1gM ANCA of undefined specificity
in association with clearly defined anti-PR3 IgO ANCA activity
(Table 2). None of the patients without 1gM ANCA at onset
suffered from pulmonary hemorrhage.
The association of 1gM with IgO ANCA in patients present-
ing with pulmonary hemorrhage does not necessarily show the
pathogenic role of the 1gM autoantibodies, since it could be
argued that patients with hemoptysis are more likely to be seen
early, compared with patients presenting with other symptoms,
who may not immediately seek medical advice. Although 1gM
autoantibodies have been detected in various human diseases
[20—261 and autoimmune strains of mice [27, 28], their biological
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activity has only occasionally been demonstrated in vitro [29,
30], and their pathogenetic role remains controversial [20, 31].
When characterized, 1gM autoantibodies have usually been
found to be of low affinity and polyreactive, like natural
autoantibodies present in normal subjects [32, 33], and the 1gM
antibodies which occur during the primary response to alloan-
tigens [34]. However, in our study, the association of 1gM
ANCA with pulmonary hemorrhage and the relatively poorer
outcome of the patients who were not treated by early removal
of the 1gM fraction suggested they may have a pathogenic role.
The specificity of ANCA in patients with pulmonary hemor-
rhage was not restricted to one particular antigen, and our
assays indicated that there was a clear cut difference in the
specificities, arguing against their sharing a common epitope.
Although anti-PR3 antibodies are closely related to Wegener's
granulomatosis with diffuse systemic involvement [35],whereas
anti-MPO antibodies can be observed in a subgroup of patients
with limited kidney vasculitis [7], anti-MPO antibodies can also
be present in patients with extensive systemic vasculitis [7, 35].
Our data also demonstrate that we cannot rate anti-PR3 anti-
bodies as more injurious than anti-MPO antibodies, since both
were associated with pulmonary hemorrhage, and the need for
ventilation and/or hemodialysis.
One explanation for the persistence of 1gM ANCA might be
delay in isotype switching to IgG, as previously described in the
patients with 1gM ANCA alone [81. Either of the regulatory
factors thought to be important in immunoglobulin class switch-
ing might be responsible for this: viz genetic factors as shown in
inbred mice [36, 37] or cytokine environment [38, 39]. Whatever
the explanation, these 1gM autoantibodies should be equally
efficient in taking part in any of the postulated pathogenic
mechanisms that have been postulated for IgG, including anti-
gen-antibody immune complex formation, as well as in situ
complement, and/or neutrophil activation.
Our data add further information about the nature of the
autoimmune response in this group of patients with systemic
vasculitis. In other studies we have observed a switch from 1gM
to IgG ANCA [8], as well as affinity maturation of ANCA IgG
subclasses [40], which suggested an antigen driven clonal
expansion as shown for SLE [41, 421. In one of the patients
described in this paper, we found 1gM anti-PR3 in association
with IgG anti-MPO, without 1gM anti-MPO or IgG anti-PR3
activity. This association of two or more specificities of ANCA
in some patients raises the question of whether there are two
separate clonal expansions or a cross reactive epitope present
on both molecules recognized by a single clone. Because in this
patient the two specificities were carried by different isotypes,
this supports the existence of two clones at different stages of
maturation. Furthermore, our data suggested that within the
population of 1gM anti-MPO autoantibodies from our patients,
there might be one dominant immunogenic epitope. However,
not all the lgG anti-MPO positive sera inhibited the 1gM
anti-MPO binding in our assay, suggesting that there is more
than one common epitope. Western blot analysis showed that
reactivity of both IgG and 1gM anti-MPO antibodies was limited
to the MPO heavy chain and competitive solid phase binding
assays showed that most of the IgO anti-MPO sera inhibited the
binding of the 1gM anti-MPO antibodies. This would add further
evidence for the generation of IgG ANCA resulting from a
switch from 1gM secreting clones in an antigen driven response.
We conclude that, in patients with systemic vasculitis, spe-
cial consideration should be given for those with 1gM ANCA,
since the presence of the latter seems to be associated with
potentially severe pulmonary disease. We propose that, when
clinically indicated, plasma exchange in patients with pulmo-
nary hemorrhage and 1gM ANCA should be performed using a
cytocentrifuge as a plasma separator device. Further studies are
now required to establish the pathogenetic role of 1gM ANCA.
Reprint requests to Dr. V. Esnault, Department of Medicine, School
of Clinical Medicine, Hills Road, Cambridge CB2 2QQ, England,
United Kingdom.
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